Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. [electronic resource]
Producer: 20120424Description: 495-7 p. digitalISSN:- 1531-4995
- Administration, Intranasal
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Bevacizumab
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Humans
- Injections
- Male
- Middle Aged
- Nasal Mucosa
- Prospective Studies
- Severity of Illness Index
- Telangiectasia, Hereditary Hemorrhagic -- diagnosis
- Treatment Outcome
- Vascular Endothelial Growth Factor A
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.